Definium Therapeutics presents positive Phase 3 data for DT120 ODT in generalized anxiety disorder
DFTX•Definium Therapeutics reported positive results from three Phase 3 studies of DT120 ODT in generalized anxiety disorder and major depressive disorder. In the Panorama study, the 100-microgram dose improved anxiety scores by 5.1 points over placebo at week 12, and the company reported cash and investments of approximately $1.05 billion as of September 30, 2026.
1. Panorama results
Definium Therapeutics said Panorama met all primary and key secondary endpoints. The 100-microgram dose improved anxiety scores by 5.1 points over placebo at week 12, with the primary endpoint reaching statistical significance at p<0.0001; no new safety signals were identified.
2. Cash position
The company reported approximately $1.05 billion in cash, cash equivalents and investments as of September 30, 2026, and said its cash runway is expected to extend into 2030.
